Quintiles Receives Award from Patient-Centered Outcomes Research Institute to Compare the Effectiven
Quintiles Receives Award from Patient-Centered Outcomes Research Institute to Compare the Effectiveness of Uterine Fibroid Treatments in Real-World Practice
Study to help patients and clinical community make better-informed decisions about patient care
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Quintiles today announced that it has received a research award from the Patient-Centered Outcomes Research Institute (PCORI) to compare the effectiveness of treatments for uterine fibroids, a common condition affecting women of childbearing age. The study is part of a portfolio of patient-centered research that addresses PCORI's national research priorities. It will provide patients and their caregivers with information that will help them make better-informed care decisions.
"More than $4 billion is spent annually to treat uterine fibroids in the United States1, yet there is little scientific evidence about which treatment options are better than others. The clinical community needs better data to demonstrate the effectiveness, quality and value of treatments in real-world clinical practice," said Richard Gliklich, MD, President, Quintiles Outcome, the real-world and late phase division of Quintiles. "With this research award we will compare patient outcomes after a variety of treatments, developing high-quality and clinically rich patient-level data to inform better care decisions."
The research will be led by Dr. Gliklich and be supported by Penny Mohr, MA, Vice President of Program Development at the Center for Medical Technology Policy, and Evan Myers, MD, MPH, Walter M. Thomas Distinguished Professor in the Department of Obstetrics and Gynecology at Duke University. The investigators will take a comprehensive approach to evidence development, analyzing more than 33,000 patient records from electronic medical records, claims data and data from integrated healthcare delivery systems. The primary objective of the study is to answer critical questions prioritized by multiple stakeholders such as how long treatment effects (that is, relief from symptoms) last for treatments other than hysterectomy, as well as for all treatments, including hysterectomy.
"This project reflects PCORI's commitment to support patient-centered comparative effectiveness research, a new approach to health research that emphasizes the inclusion of patients and caregivers at all stages of the study process," said PCORI Executive Director Joe Selby, MD, MPH. "The research will provide patients and those who care for them with better information about the healthcare decisions they face."
The Quintiles study was selected through a highly competitive review process in which scientists, patients, caregivers, and other stakeholders helped to evaluate more than 400 applications for funding. Proposals were evaluated on the basis of scientific merit, how well they engage patients and other stakeholders, their methodological rigor, and how well they fit within PCORI's national research priorities.
The awards are part of PCORI's second cycle of primary research funding totaling $88.6 million. This new round of funding follows PCORI's initial approval of $40.7 million in support for 25 projects under the institute's national research priorities. All awards in this most recent round of funding were approved pending completion of a business and programmatic review by PCORI staff and issuance of a formal award contract. For more information about PCORI's Funding Announcements, visit www.pcori.org/funding-opportunities.
The Patient-Centered Outcomes Research Institute (PCORI) is an independent, non-profit organization authorized by Congress in 2010. Its mission is to fund research that will provide patients, their caregivers and clinicians with the evidence-based information needed to make better-informed healthcare decisions. PCORI is committed to continuously seeking input from a broad range of stakeholders to guide its work. More information is available at www.pcori.org.
Quintiles (NYS: Q) is the world's largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 27,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top 50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes.
1 Cardozo ER, Clark AD, Banks NK, Henne MB, Stegmann BJ, Segars JH. The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol 2012;206:211 e1-9.
Click here to subscribe to Mobile Alerts for Quintiles.
KEYWORDS: United States North America North Carolina
The article Quintiles Receives Award from Patient-Centered Outcomes Research Institute to Compare the Effectiveness of Uterine Fibroid Treatments in Real-World Practice originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.